Day: August 25, 2022

CALGARY, Alberta, Aug. 25, 2022 (GLOBE NEWSWIRE) — Razor Energy Corp. (“Razor” or the “Company”) (TSXV: RZE) announces its second quarter 2022 financial and operating results. Selected financial and operational information is outlined below and should be read in conjunction with Razor’s unaudited interim condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended June 30, 2022 which are available on SEDAR at www.sedar.com and the Company’s website www.razor-energy.com. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See “Non-IFRS and Other Financial Measures” below. RECENT HIGHLIGHTSIncreased Production: Completed work on a group pipeline and associated wells in...

TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or “Blueberries“), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management’s discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted. Blueberries Medical Corp. continues to deploy its strategy by focusing on multiple key revenue-generating activities while reducing...

TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) — Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three and six months ended June 30, 2022 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund’s focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company’s assets are located in Toronto, Brampton, Belleville,...

CALGARY, Alberta, Aug. 25, 2022 (GLOBE NEWSWIRE) — CVW CleanTech Inc. (the “Company” or “CVW CleanTech”) (TSX-V: CVW)  is pleased to announce its operating and financial results the three and six month periods ended June 30, 2022. For complete details, please refer to the condensed interim financial statements and the associated Management Discussion and Analysis for the period ended  June 30, 2022, available on SEDAR: (www.sedar.com) or on the Company’s website: www.CVWCleanTech.com/ Management and the Board of Directors continue to seek to commercialize CVW CleanTech’s technologies, to a broader range of partners than previously contemplated. Further, we are considering application of its technologies and financial structuring to a broader clean tech industry. Financial highlightsThe cash balance...

MILWAUKEE, Aug. 25, 2022 (GLOBE NEWSWIRE) — Koss Corporation (NASDAQ: KOSS) (the “Company”), the U.S. based high-fidelity headphone company, has reported its results for the fourth quarter ended June 30, 2022. Sales for the fourth fiscal quarter were $4,191,761, a decline of 22.7% compared to $5,420,471 for the same period in the prior year. The net income for the three months ended June 30, 2022 was $385,595, which is an increase over the net income of $331,943 for the same three month period one year ago. Both basic and diluted income per common share for the quarter were $0.04 compared to a basic income per common share of $.04 and a diluted income per common share of $0.03 for the three-month period one year ago. “We saw a decline in sales for the quarter,” Michael J. Koss, Chairman and CEO, said today. “We appear to be experiencing...

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers; next-generation T-cell engagers; and antiviral DARPins MP0310 Phase 1 enrollment complete; no additional studies currently planned In January 2022, Molecular Partners received a payment of CHF 150 million from Novartis to license ensovibep Novartis is responsible for further development, manufacturing, and commercialization activities. An application for Emergency Use Authorization (EUA) was submitted to the U.S. Food and Drug Administration (FDA) by Novartis for ensovibep Cash position of CHF 285.1 million as of June 30, 2022, anticipated to support operations...